SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: ER+ HER2- Advanced Breast Cancer
Interventions: DRUG: SHR9549
Sponsor: Jiangsu HengRui Medicine Co., Ltd.